Top 5 Weight Loss Injections Approved in Canada

Canada offers Americans access to five weight loss injections at lower costs: Wegovy, Saxenda, Zepbound, Ozempic, and Mounjaro. These medications utilize GLP-1 and dual-action GIP mechanisms to achieve significant weight reduction, ranging from 14 to 25 kilograms at the time of being combined with lifestyle changes.

Each option requires medical supervision and follows specific dosing protocols. Understanding the unique benefits and requirements of each medication reveals their full potential for effective weight management.

Key Takeaways

Wegovy (Semaglutide) offers 16-18% weight loss and is approved in Canada at potentially lower costs than U.S. prices.
Saxenda (Liraglutide) provides daily weight management with gradual dose escalation and is accessible through Canadian pharmacies.
Zepbound (Tirzepatide) will be available in Canada by May 2025, promising competitive pricing compared to U.S. costs over $1,000 monthly.
Ozempic (Semaglutide) is widely available in Canada for diabetes treatment with off-label weight loss benefits averaging 14 pounds.
Mounjaro (Tirzepatide) shows superior weight loss results of 25kg and can be accessed through Canadian sources at reduced costs.

Wegovy (Semaglutide): Canada’s First Obesity-Focused GLP-1 Injection

In a significant advancement for obesity treatment in Canada, Wegovy (semaglutide injection) received Health Canada authorization on November 23, 2021, marking the country's initial approval of a GLP-1 receptor agonist specifically for weight management.

This groundbreaking medication serves as an adjunct to lifestyle modifications for adults with a BMI of ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. Clinical trials demonstrated impressive results, with non-diabetic individuals achieving 16-18% weight loss during the combination with lifestyle changes. The once-weekly injection works by mimicking natural hormones that regulate appetite and food intake.

Healthcare providers can prescribe Wegovy using a gradual dose escalation approach over 16-20 weeks, reaching an ideal dose of 2.4 mg. This strategic approach helps minimize common side effects while maximizing the medication's effectiveness in obesity management, offering new hope for those struggling with weight-related health challenges.

Saxenda (Liraglutide): Daily Weight Management for Steady, Sustainable Results

Following Wegovy's introduction to the Canadian market, another significant weight management option, Saxenda (liraglutide), offers patients a daily approach to sustainable weight loss. This Health Canada-approved obesity treatment functions like a GLP-1 receptor agonist, effectively regulating appetite and supporting weight management goals through controlled hormone mimicry.

Saxenda addresses chronic disease management for individuals with a BMI of 30 kg/m² or higher, or 27 kg/m² with weight-related complications. The medication follows a gradual dose escalation protocol, starting at 0.6 mg daily and increasing to 3 mg over four weeks, allowing the body to adapt to the treatment.

As part of a thorough health support system, it works alongside lifestyle modifications, including reduced-calorie diets and increased physical activity. While common side effects include nausea and diarrhea, proper medical supervision and patient education help guarantee ideal outcomes in long-term weight management.

Zepbound (Tirzepatide): Canada’s Newest Dual-Action Powerhouse for Obesity

The latest breakthrough in obesity treatment arrives in Canada while Zepbound (tirzepatide) secures Health Canada approval in May 2025. This innovative medication represents a significant progression in obesity management, functioning as a dual-action GIP and GLP-1 receptor agonist.

Zepbound's powerful mechanism improves insulin secretion while reducing glucagon levels, leading to impressive weight loss results that potentially surpass other medications in its class. As the initial combination peptide approved for obesity management, it offers extensive metabolic benefits beyond weight reduction, including improved insulin sensitivity.

Administered through weekly injections, Zepbound builds upon the success of its diabetes-focused counterpart, Mounjaro, which contains the same active ingredient. While cost remains a consideration, with U.S. prices exceeding $1,000 monthly, Canadian accessibility may offer more affordable options for those seeking effective weight management solutions through authorized imports or local purchases.

Ozempic (Semaglutide): Off-Label Weight Loss with Diabetes Benefits

Widely prescribed for diabetes management, Ozempic has emerged as a significant player in Canada's weight loss landscape through its off-label use. This injectable medication contains semaglutide, a GLP-1 receptor agonist that effectively controls blood sugar while promoting weight loss effects through appetite suppression and delayed gastric emptying.

While primarily indicated for type 2 diabetes, Ozempic's demonstrated ability to achieve substantial weight reduction has made it a sought-after option among obesity medications. Clinical studies reveal impressive results, with patients losing an average of 14 pounds over 40 weeks. Beyond weight management, the medication offers additional benefits, including cardiovascular protection and kidney disease prevention.

Although not officially approved for weight loss in Canada as its counterpart Wegovy, Ozempic's accessibility and established safety profile have made it a practical choice for off-label weight loss prescriptions, often at a more favorable cost compared to U.S. alternatives.

Mounjaro (Tirzepatide): Zepbound’s Twin for Diabetes-Driven Weight Loss

Representing a significant advancement in diabetes and weight management treatment, Mounjaro (tirzepatide) harnesses a unique dual-action approach by targeting both GLP-1 and GIP receptors. This innovative mechanism delivers superior results compared to single-receptor medications, with clinical trials showing an average weight loss of 25 kg from a baseline weight of 105 kg.

While Mounjaro is currently approved in Canada for type 2 diabetes treatment, medical professionals may prescribe it off-label for obesity management. The medication's active ingredient, available as Zepbound in the U.S., demonstrates remarkable effectiveness in treating patients with a BMI ≥30 or ≥27 with weight-related conditions. Its dual-receptor activation improves metabolic control, suppresses appetite, and increases insulin sensitivity more effectively than traditional GLP-1 medications. For Americans seeking cost-effective alternatives, accessing Mounjaro through Canadian sources may offer a viable solution for diabetes-driven weight loss management.

Frequently Asked Questions

Can I Drink Alcohol While Taking Weight Loss Injections?

Alcohol is not recommended with weight loss injections due to:

Increased medication side effects
Reduced weight loss effectiveness
Risk of dangerous blood sugar fluctuations

How Long Should I Wait Between Switching Different Weight Loss Medications?

Wait three months between weight loss medications to assess effectiveness and monitor side effects. Consult doctor before switching.

Will My Insurance Cover These Medications if Purchased From Canada?

U.S. insurance plans do not cover medications from Canada. Canadian insurance requires prior authorization and documentation for weight loss medication coverage through approved providers.

What Happens to Weight Loss Progress if I Stop Taking Injections?

Weight regain occurs after stopping semaglutide injections, typically within one month. Tapering doses while maintaining diet and exercise may help preserve some weight loss.